XML 49 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2022
Shareholders' Equity (Tables) [Line Items]  
Schedule of issued and outstanding
   December 31, 2022   December 31, 2021 
   Authorized   Issued and Outstanding   Authorized   Issued and Outstanding 
Ordinary shares   100,000,000    55,094,237    100,000,000    51,791,441 
Total   100,000,000    55,094,237    100,000,000    51,791,441 

 

Schedule of share-based awards to employees, officers and directors
   Year ended
December 31,
2022
 
   Number of   Weighted 
   share-based   average 
   payment   exercise 
   awards   price 
Outstanding at beginning of year   2,324,243   $6.17 
Changes during the year:          
Granted   20,000    17.63 
Exercised   (423,702)   2.08 
Forfeited   (82,469)   11.86 
Expired   -    - 
Cancelled   -    - 
Outstanding at end of year   1,838,072    8.77 
Aggregate intrinsic value   7,669      
Exercisable at end of year   1,582,254    11.23 
Aggregate intrinsic value   7,235      

 

Schedule of Black-Scholes option-pricing model
   Year ended
December 31,
2022
   Year ended
December 31,
2021
 
Dividend yield   0    0 
Expected volatility   52.37-52.75%   50.27% - 52.71%
Risk-free interest rate   3.45-3.51%   0.66% - 1.61%
Expected term (years)   10    10 

 

   2022   2021 
Dividend yield  0   0 
Expected volatility   50.75% - 52.69%   50.27%-51.84%
Risk-free interest rate   1.52% - 4.34%   0.66%-1.61%
Expected term (years)   5.52-10    6.25 

 

Schedule of information concerning outstanding and exercisable awards
December 31, 2022 
Awards outstanding   Awards exercisable 
    Number of   Weighted   Number of   Weighted 
    awards   average   award   average 
    outstanding   remaining   exercisable   remaining 
Exercise   at end of   contractual   at end of   contractual 
price   year   life (years)   year   life (years) 
                  
$2.21    1,483,416    7.71    1,399,414    7.75 
$16.00    156,484    5.96    101,410    5.21 
$17.63    20,000    9.81    -    - 
$23.19    21,000    8.78    5,250    8.78 
$23.84    30,000    8.88    7,500    8.88 
$30.93    20,000    7.81    20,000    7.81 
$40.21    7,172    8.19    4,930    8.19 
$49.68    100,000    8.05    43,750    8.05 

 

December 31, 2022
Awards outstanding   Awards exercisable 
   Number of   Weighted   Number of   Weighted 
   awards   average   awards   average 
   outstanding   remaining   exercisable   remaining 
Exercise  at end of   contractual   at end of   contractual 
price  year   life (years)   year   life (years) 
$  0.00-0.01    28,952*)   -    19,219                 - 
$  2.21    1,053,594    6.95    982,445    6.94 
$  16.00    110,999    8.45    43,967    7.07 
$  17.63    897,265    9.63    20,738    9.4 
$  23.19    189,000    8.78    47,250    8.78 
$  23.42    16,000    8.77    4,000    8.77 
$  23.84    625,943    9.06    112,310    8.89 
$  23.86    69,400    8.75    17,350    8.75 
$  24.97    21,900    8.42    8,919    8.42 
$  28.96    18,875    7.85    18,875    7.85 
$  30.66    34,000    8.53    10,623    8.53 
$  36.74    3,000    7.93    1,500    7.93 
$  40.21    37,900    8.19    16,579    8.19 
$  49.68    133,000    8.05    43,750    8.05 
$  59.2    13,000    8.17    6,312    8.15 
$  64.61    25,010    8.12    10,940    8.12 

 

*) Including 22,778 RSUs that were granted to the employees of Nanox AI at the completion of the merger and 3,221 RSUs that were issued in consideration for services.

 

Schedule of share-based compensation expenses
   Year Ended December 31, 
   2022   2021   2020 
   (U.S. dollars in thousands) 
Cost of revenue   99    51    - 
Research and development   4,806    3,248    3,384 
Sales and Marketing (*)   997    2,442    9,252 
General and administrative   12,721    13,065    12,145 
                
    18,623    18,806    24,781 

 

(*)

On October 26, 2020, the Company entered into an amendment to a business development agreement (“the BD Agreement”) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision) and expiration date of November 8, 2024. As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the BD Agreement and all activities undertaken on behalf of the Company, including the right to a percentage from future revenues from any of the Company’s systems and the issuance of warrants.

Employees, Officers and Directors [Member]  
Shareholders' Equity (Tables) [Line Items]  
Schedule of issued and outstanding
   Year ended 
   December 31, 2022 
   Number of   Weighted 
   share-based   average 
   payment awards   exercise
price
 
Outstanding at beginning of year   2,760,930   $15.85 
Changes during the year:          
Granted   1,266,803   $19.00 
Exercised   (141,384)   1.18 
Forfeited   (608,511)   22.20 
Expired   -    - 
Cancelled   -    - 
Outstanding at end of year   3,277,838   $18.79 
Aggregate intrinsic value  $5,660      
Exercisable at end of year   1,364,777   $9.51 
Aggregate intrinsic value  $5,221